India to crack the whip against firms flouting drug safety reporting norms
This article was originally published in Scrip
Call it the effect of the damning Parliamentary committee report or maybe just part of concerted efforts to improve the country's regulatory system, but the Drugs Controller General of India (DCGI) has decided to crack the whip against firms that donot take their safety reporting obligations seriously.
You may also be interested in...
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.